公司名稱: 凱萊英醫藥集團（天津）股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]

一、董事会会议召开情况 证券代码：002821 证券简称：凯莱英 公告编号：2025-038 凯莱英医药集团（天津）股份有限公司 第四届董事会第六十四次会议决议的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第四届董事会 第六十四次会议通知于 2025 年 6 月 27 日以电子邮件及书面等形式发送给各位 董事、监事及高级管理人员，会议于 2025 年 7 月 4 日以通讯表决方式召开。公 司应到董事 9 名，实到董事 9 名，公司监事及高级管理人员列席了本次会议。会 议由公司董事长 HAO HONG 先生召集和主持，会议的召集和召开符合《公司法》 及相关法律、法规以及《公司章程》的有关规定。 二、董事会议案审议情况 会议采用通讯方式进行表决，经全体董事审议，通过了如下决议： 1、审议通过了《关于变更部分募集资金用途暨新增募集资金投资项目、调 整部分项目投资金额及延期的议案》 为了进一步提高募集资金使用效率，综合考虑市场情况、行业环境及公司实 际经营需要，公司拟变更募投项目"凯莱英药业（江苏）有限公司生 ...

凯莱英医药集团（天津）股份有限公司 关于变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期的公告 证券代码：002821 证券简称：凯莱英 公告编号：2025-040 联交易，亦不属于《上市公司重大资产重组管理办法》规定的重大资产重组。现 将有关情况公告如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医 药集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价 为 227.00 元/股，募集资金总额为人民币 2,310,571,937.00 元，扣除承销费用 （不含税）32,696,772.70 元，公司实际收到募集资金人民币 2,277,875,164.30 元，扣除其他发行费用人民币 2,914,508.24 元，实际募集资金净额为人民币 2,274,960,656.06 元。上述资金到账情况业经容诚会计师事务所（特殊普通合 伙）出具容诚验字[2020]100Z0073 号《验资报告》验证。 本 ...

第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期事项的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"）的保 荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》、《上市公司募集资金监管规则》等法律和规范性文件的要求，对凯莱英医 药集团（天津）股份有限公司变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期情况进行了审慎核查。具体情况如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医药 集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月 向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价为 227.00 元/股，募集资金总额为人民币 2,310,57 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-041 凯莱英医药集团（天津）股份有限公司 关于调整部分 H 股募投项目实施地点、 投资金额及延期的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在 虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召开第四届董事会第六十四次会议，审议通过了《关于调整部分 H 股募投项目实 施地点、投资金额及延期的议案》。为提高 H 股募集资金使用效率，公司逐步进行项 目布局、稳步推进项目实施，在对相关项目的进展进行动态评估后，拟对部分 H 股募 投项目的投资金额进行调整及延期。该事项尚需提交股东大会审议批准。现将有关事 项公告如下： 一、 调整部分 H 股募投项目实施地点、投资金额及延期基本情况 单位：百万人民币 | 募投项目名称 | 变更前 | 变更前拟使 用募集资金 | 变更后 | 变更后拟使 用募集资金 | 变更前 | | 变更后 完成时 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-039 凯莱英医药集团（天津）股份有限公司 第四届监事会第五十一次会议决议公告 本公司及全体监事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第四届监事会 第五十一次会议通知于 2025 年 6 月 27 日以电子邮件及书面报告等形式发送给各 位监事，会议于 2025 年 7 月 4 日以通讯方式召开。公司应到监事 3 名，实到监 事 3 名，会议由公司监事会主席智欣欣女士召集，会议的召集和召开符合《公司 法》及相关法律、法规以及《公司章程》的有关规定。 二、 监事会会议审议情况 会议采用通讯方式进行了表决，经全体监事审议并表决，通过了如下决议： 1、审议通过了《关于变更部分募集资金用途暨新增募集资金投资项目、调 整部分项目投资金额及延期的议案》 经审核，监事会认为：公司本次变更部分募集资金用途暨新增募集资金投资 项目，并调整部分募投项目投资金额及项目延期事项是公司出于长远发展战略做 出的慎重决策，有利于提高募集资金使用效率，符合公司及全体 ...

商保创新药目录呼之欲出，内需市场有望迎来明显改善，持续推荐创新药及产业链。 投资要点： 利好不断，持续推荐创新药及产业链 [Table_Industry] 医药 ——HTI 医药 2025 年 7 月月报 [Table_subIndustry] 细分行业评级 本报告导读： 请务必阅读正文之后的免责条款部分 股 票 行 研 究 报 告 股票研究 /[Table_Date] 2025.07.02 [Table_Invest] 业 月 报 证 券 研 究 [table_Authors] 2025-07-03 [Table_Summary] 利好不断，持续推荐创新药及产业链。维持以下 A 股标的优于大市 评级并将其纳入 HTI 医药 2025 年 7 月月度组合：恒瑞医药、科伦药 业、华东医药、药明康德、凯莱英、泰格医药、惠泰医疗。维持以 下 H 股标的优于大市评级：科伦博泰生物、翰森制药、信达生物、 药明合联、映恩生物、百济神州，相关标的：药明康德、康哲药业。 商保创新药目录呼之欲出，内需市场有望迎来明显改善。经国务院 同意，7 月 1 日国家医保局、国家卫健委联合发布《支持创新药高 质量发展的若干措施》，重点提出 ...

Summary of Conference Call Records Industry Overview - The innovative drug industry chain is gradually stabilizing and recovering, with CXO orders rebounding since last year, leading to strong mid-year performance in key segments [1][2][3] - The overall trend for the pharmaceutical sector in Q2 2025 is positive, particularly in innovative drugs and their supply chains, despite recent market fluctuations [2][3] Key Companies and Performance - **Hengrui, Huadong, and China Biopharmaceutical** are expected to achieve double-digit growth in Q2 and for the entire year [1][6] - **WuXi AppTec** aims for a revenue target of 43 billion, with an expected growth of over 15% and faster net profit growth; **WuXi AppTec's** revenue growth is projected at over 35% for the year [1][11] - **Kelaiying** anticipates a revenue growth of over 15% for the year, while **Kanglong Huacheng** expects around 10% growth in revenue and profit for Q2 [1][11][13] - **BaiPuSi and Haoyuan Pharmaceutical** are performing well, with most companies expecting revenue growth of over 20% [1][15] Market Catalysts - Recent adjustments in medical insurance policies and industry conferences (WCLC, ESMO, Ash) are seen as potential catalysts for growth in the innovative drug sector [1][7][9] - The upcoming medical insurance negotiations and directory adjustments are expected to be significant driving forces in the second half of the year [9][10] Investment Opportunities - Despite a recent decline in market sentiment, large-cap companies like **BaiJi, Hengrui, XinDa, Kangfang, and Shiyao** are recommended for investment, along with smaller companies like **Dizhe and Yifangzejin** [10] - The CXO and upstream sectors are highlighted as key investment areas, with strong performance expected due to improved orders and geopolitical factors [19][20] Sector Performance - The medical device sector is still in a clearing inventory phase, with some companies showing good growth, particularly in overseas markets [17][18] - The OTC and traditional Chinese medicine sectors have not shown significant improvement but may see recovery in the second half of the year [5][18] Future Outlook - The overall outlook for the second half of 2025 remains optimistic, with expectations of continued growth in the innovative drug sector and supportive external factors [9][24] - The domestic financing environment is expected to improve, with a notable increase in activity anticipated in the latter half of the year [26][38] Conclusion - The innovative drug industry chain, particularly the CXO segment, is positioned for strong growth, supported by favorable market conditions and strategic company performances. Investors are encouraged to focus on key players within this sector for potential opportunities.

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]